Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Nanobiotix    NANO   FR0011341205


Delayed Quote. Delayed  - 10/27 10:46:18 am
14.77 EUR   +0.48%
10/20 NANOBIOTIX : 's partner, PharmaEngine, has launched a new NBTXR3 cli..
10/20 NANOBIOTIX : Scientific Clinical | Nanobiotix’s partner, Pharm..
09/19 NANOBIOTIX : Financial | Bpifrance grants Nanobiotix a 2M€ interest-..
News SummaryMost relevantAll newsSector news 

NANOBIOTIX : and the CLARA, partners of ETPN for the organization of the Nano World Cancer Day

share with twitter share with LinkedIn share with facebook
share via e-mail
01/28/2013 | 08:40am CEST
Nanobiotix and the CLARA, partners of ETPN for the organization of the Nano World Cancer Day


An event organized by the European Technology Platform of Nanomedicine in the framework of the World Cancer Day

Paris and Lyon, France, January 28th, 2013 - Nanobiotix and the Lyon Auvergne Rhône-Alpes Cancer Research Cluster (CLARA) today announce their participation to the European event on February the 1st organized by ETPN (European Technology Platform of Nanomedicine). Similar events will be organized in parallel across Europe: France, United Kingdom, Germany and Portugal. Nano World Cancer Day is an event organized by the ETPN highlighting the importance of nanomedicine research for cancer on the European level.

"How nanomedicine contributes to better cancer diagnostic and therapy"

Radiotherapy, chemotherapy and surgery are part of the therapeutic arsenal for patients with cancer. New technologies associated with nanoparticles could provide more effective solutions to personalize diagnoses and treat these diseases, while improving targeted drug delivery and reducing side effects and collateral damages on the body. These breakthrough therapies based on nanomedicine contribute to solving this paradigm and are already a reality, with concrete results, 60 nano-products on the market and more than 70 in the pipeline. Nanomedicine can go further in bringing new therapeutic mode of action into cells. For instance, nanoparticles can already be injected into the tumor and then be activated to produce physical effect and destroy cancer cells locally.

Across the parallel European press events, leading international actors in the field will introduce examples highlighting the key role of nanomedicine for cancer therapy, diagnoses and imaging. This year, these actors across Europe are:

National Cancer organizations: CLARA (FR), Comprehensive Cancer Center (Charité University Hospital) (DE), International Iberian Nanotechnology Laboratory (PT) and Instituto Português de Oncologia do Porto (PT).

SMEs: Nanobiotix (FR & DE).

Universities / Public laboratories: Thomas Jefferson University, Philadelphia, US (FR), Université Paris Sud, Institut Galien Paris-Sud / CNRS (FR), Ludwig-Maximilians University München (DE), Aachen University Hospital (DE), Universidad de Santiago de Compostela (Spain), University of Lisboa/ Faculty of Pharmacy (PT), Leeds University (UK).

 Leading local experts involved in the Paris event:

-          Dr. Amaury MARTIN, Secretary General of CLARA (Lyon Rhône-Alpes Auvergne Cancer Research Cluster), Lyon

-          Dr. Laurent LEVY, Vice Chairman ETPN, CEO of Nanobiotix, Paris

-          Pr. Bo LU, MD, Thomas Jefferson University Hospital, Professor in the Department of Radiation Oncology and Director of the department's Division of Molecular Radiation Biology, Philadelphia

-          Pr. Elias FATTAL, Paris Sud University, Institut Galien Paris-Sud, CNRS-UMR 8612, Faculty of Pharmacy, Châtenay-Malabry.

This conference will give an overview on nanomedicine for cancer: what are the key areas of research? What are the new methods of diagnosis? What are the new treatments in development? What are the first results? What are the products used every day?

Videos of the Paris event will be available on February the 4th 2013 for the World Cancer Day.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NANOBIOTIX
10/20 NANOBIOTIX : 's partner, PharmaEngine, has launched a new NBTXR3 clinical trial ..
10/20 NANOBIOTIX : Scientific Clinical | Nanobiotix’s partner, PharmaEngine, has..
09/19 NANOBIOTIX : Financial | Bpifrance grants Nanobiotix a 2M€ interest-free loan to..
09/19 Bpifrance grants Nanobiotix a 2MEU interest-free loan to support final develo..
09/19 NANOBIOTIX : Bpifrance grants Nanobiotix a 2M€ interest-free loan to support fin..
09/13 NANOBIOTIX : Corporate | Nanobiotix announces submission for first market approv..
08/31 NANOBIOTIX : Financial | Nanobiotix half year results for the six months ended 3..
08/26NANOBIOTIX SA : half-yearly earnings release
07/13 NANOBIOTIX : Financial | Nanobiotix revenue for Q2 2016
07/08NANOBIOTIX SA : half-yearly sales release
More news
Sector news : Biotechnology & Medical Research - NEC
10/25DJMERCK : Profit Rises on Cancer Drugs, Vaccines
10/21DJU.S. HOT STOCKS : Hot Stocks to Watch
10/20DJALKERMES : Shares Surge
10/20 ACTELION : raises guidance for third time this year on strong PAH sales
10/18 Pfizer to start shipping biosimilar version of J&J's Remicade in November
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
2015 NANOMETRICS : Well-Positioned In A Promising Industry
2015 Nanometrics' (NANO) CEO Timothy Stultz on Q4 2014 Results - Earnings Call Tra..
2015 Nanometrics Incorporated (NANO) Q4 2014 Results - Earnings Call Webcast
2015 Nanometrics beats by $0.03, beats on revenue
2015 Notable earnings after Monday?s close
Financials (€)
Sales 2016 5,63 M
EBIT 2016 -17,3 M
Net income 2016 -16,2 M
Finance 2016 8,12 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 39,4x
EV / Sales 2017 18,6x
Capitalization 230 M
More Financials
Duration : Period :
Nanobiotix Technical Analysis Chart | NANO | FR0011341205 | 4-Traders
Full-screen chart
Technical analysis trends NANOBIOTIX
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus BUY
Number of Analysts 5
Average target price 33,7 €
Spread / Average Target 129%
Consensus details
EPS Revisions
More Estimates Revisions
Laurent Lévy Chief Executive Officer
Laurent Condomine Chairman-Supervisory Board
Philippe Mauberna Chief Financial Officer
Elsa Borghi Chief Medical Officer
Christophe Douat Member-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.--.--%10 775
LONZA GROUP AG8.71%9 380
ALKERMES PLC-32.93%8 069
More Results